Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al

Badawi Mohamed; Coss Christopher C.; Phelps Mitch A.

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al

【24h】

Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al

机译：致编辑的信：免疫检查点治疗中的曝光响应或间隙 - 反应关系？-A basak等人的Nivolumab暴露与治疗结果之间的相关性。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共2页
作者
Badawi Mohamed; Coss Christopher C.; Phelps Mitch A.;
展开▼
作者单位

Ohio State Univ Coll Pharm Div Pharmaceut &

Pharmaceut Chem 500 W 12Th Ave Columbus OH 43210;

Ohio State Univ Coll Pharm Div Pharmaceut &

Pharmaceut Chem 500 W 12Th Ave Columbus OH 43210;

Ohio State Univ Coll Pharm Div Pharmaceut &

Pharmaceut Chem 500 W 12Th Ave Columbus OH 43210;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al [J] . Badawi Mohamed, Coss Christopher C., Phelps Mitch A. European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：致编辑的信：免疫检查点治疗中的曝光响应或间隙 - 反应关系？-A basak等人的Nivolumab暴露与治疗结果之间的相关性。
2. EXPOSURE-RESPONSE (E-R) ANALYSIS OF OVERALL SURVIVAL (OS) FOR NIVOLUMAB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) [J] . Feng Y., Bajaj G., Agrawal S., Clinical Pharmacology and Therapeutics . 2016,第Suppla1期

机译：曾接受过治疗或转移性非小细胞肺癌（NSCLC）的患者利福单抗总体生存率（OS）的暴露-响应（E-R）分析
3. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial [J] . Rizvi Naiyer A., Mazieres Julien, Planchard David, The lancet oncology . 2015,第3期

机译：抗PD-1免疫检查点抑制剂nivolumab对晚期难治性鳞状非小细胞肺癌（CheckMate 063）患者的活性和安全性：第2阶段单臂试验
4. CT image fusion in the optimization of replanning during the course of 3-dimensional conformal radiotherapy for non-small-cell lung cancer [C] . Xu XiMing, Deng JunJian, Guo HongTing, 2010 3rd International Conference on Biomedical Engineering and Informatics . 2010

机译：非小细胞肺癌3D立体适形放疗过程中CT图像融合对重新计划的优化
5. Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies [D] . Wang, Zixu. 2019

机译：EGCG和DAC组合治疗对治疗三重阴性乳腺癌的影响及辅助免疫检查点梗阻疗法
6. Editors choice: Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized multicenter open-label phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer [O] . L. Paz-Ares, M. A. Socinski, J. Shahidi, -1

机译：编辑选择：SQUIRE中EGFR表达与安全性和疗效结果的相关性：吉西他滨-顺铂加尼妥单抗与单独吉西他滨-顺铂在IV期患者一线治疗中的随机多中心开放标签III期研究鳞状非小细胞肺癌
7. Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy [O] . Di Wu, Chongyang Duan, Fenfang Wu, 2017

机译：在二线治疗中具有野生型表皮生长因子受体的晚期非小细胞肺癌优选哪种处理？比较免疫检查点抑制剂，酪氨酸激酶抑制剂和化疗的荟萃分析

Letter to the Editor: Exposure-response or clearance-response relationship in immune checkpoint therapy?-A comment on 'correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer' by Basak et al

著录项

相似文献

相关主题

期刊订阅